Zogenix, Inc.
5959 Horton St 5th floor
Emeryville
California
94608
United States
Website: http://www.zogenix.com/
Email: info@zogenix.com
335 articles about Zogenix, Inc.
-
Zogenix to Release First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5
4/28/2020
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the first quarter ended March 31, 2020, after the market close, and will host a corporate update conference call and webcast on Tuesday, May 5, 2020, at 4:30 PM Eastern Time. Conference Call Details Tuesday, May 5, at 4:30 PM Eastern Time / 1:30 PM Pacific Time
-
Zogenix Appoints Shawnte Mitchell as Executive Vice President, General Counsel & SecretaryNew in-house role will lead Zogenix Legal team and serve as a member of the Executive Team
4/20/2020
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has appointed Shawnte M. Mitchell to the role of Executive Vice President, General Counsel and Secretary. In this role, Ms. Mitchell will lead the company’s Legal team, manage certain corporate affairs, and serve as a member of the Zogenix Executive Team. “I am very pleased to welcome Shawnte to Zogenix,” said Stephen J. Fa
-
Zogenix to Host Investor Conference Call and Webcast on Two Studies Evaluating FINTEPLA® in Dravet Syndrome and Sunflower Syndrome
4/15/2020
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it will host an investor conference call and webcast on two studies evaluating its investigational drug, FINTEPLA®, in Dravet syndrome and Sunflower syndrome, on Wednesday, April 22, 2020, at 1:00 PM ET. Stephen J. Farr, Ph.D., President and CEO of Zogenix, will join Joseph Sullivan, M.D., UCSF Benioff Children's Hospital
-
The U.S. Food and Drug Administration has a busy week of possible drug approvals on its calendar. Here’s a look.
-
Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - March 06, 2020
3/6/2020
Zogenix, Inc., a global pharmaceutical company developing rare disease therapies, announced that it has closed its previously announced underwritten public offering of 9,798,000 shares of its common stock, including 1,278,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $23.50 per share.
-
Zogenix Prices Public Offering of Common Stock - March 03, 2020
3/4/2020
Zogenix, Inc., a global pharmaceutical company developing rare disease therapies, announced that it has priced an underwritten public offering of 8,520,000 shares of its common stock at a price to the public of $23.50 per share.
-
Zogenix Announces Proposed Public Offering of Common Stock
3/3/2020
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
-
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
3/2/2020
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today provided a corporate update and announced financial results for the quarter and full-year ended December 31, 2019.
-
Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet SyndromePDUFA target action date extended by three months to June 25, 2020
2/27/2020
Zogenix, Inc., a global pharmaceutical company developing rare disease therapies, announced that the U.S. Food and Drug Administration has extended the review period for the New Drug Application for FINTEPLA® for the treatment of seizures associated with Dravet syndrome.
-
Zogenix to Release Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call and Webcast on March 2
2/24/2020
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2019, after the market close, and will host a corporate update conference call and webcast on Monday, March 2, 2020, at 4:30 PM Eastern Time.
-
Clinical Catch-Up: February 3-7, 2020
2/10/2020
Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look. -
Emeryville, California-based Zogenix announced positive topline data from its Phase III trial of Fintepla (fenfluramine) in Lennox-Gastaut Syndrome (LGS).
-
Zogenix Announces Positive Top-line Results from Global Pivotal Phase 3 Trial of FINTEPLA® for the Treatment of Lennox-Gastaut Syndrome
2/6/2020
Primary Endpoint Achieved - Statistically Significant Reduction in Drop Seizures for FINTEPLA 0.7 mg/kg/day versus Placebo
-
Clinical Catch-Up: December 16-20
12/23/2019
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look. -
The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome
12/18/2019
FINTEPLA as adjunctive therapy showed a significant, dose-dependent reduction in convulsive seizure frequency in Dravet syndrome patients versus placebo
-
Clinical Catch-Up: December 2-5
12/9/2019
It was, as usual, a pretty busy week in clinical trial news. Here’s a look. -
Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting
12/5/2019
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor Update Lunch on its investigational drug, FINTEPLA® (ZX008, fenfluramine oral solution), on Monday, December 9, 2019, from 12:00 PM to 2:00 PM ET
-
Zogenix to Present New Data for Its Investigational Drug FINTEPLA® at the American Epilepsy Society Annual Meeting
12/2/2019
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced that data from eight abstracts related to its investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution), for the treatment of seizures associated with Dravet syndrome will be presented at the American Epilepsy Society (AES) Annual Meeting being held in Baltimore, MD, from December 6-10, 2019.
-
JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens
12/2/2019
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that JAMA Neurology has published the results of Zogenix’s Phase 3 study (Study 1504) of the investigational drug, FINTEPLA® (ZX008, fenfluramine oral solution
-
Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference
11/27/2019
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Thursday, December 5, 2019, at the 31st Annual Piper Jaffray Healthcare Conference, taking place December 3-5, 2019, in New York City.